JP7183291B2 - 局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物 - Google Patents
局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物 Download PDFInfo
- Publication number
- JP7183291B2 JP7183291B2 JP2020550596A JP2020550596A JP7183291B2 JP 7183291 B2 JP7183291 B2 JP 7183291B2 JP 2020550596 A JP2020550596 A JP 2020550596A JP 2020550596 A JP2020550596 A JP 2020550596A JP 7183291 B2 JP7183291 B2 JP 7183291B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- muscle
- polypeptide
- muscle atrophy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims (12)
- SEQ ID NO: 8と少なくとも90%の配列同一性を有する第1ポリペプチドと、
SEQ ID NO:14で規定される配列の6から10の繰返し単位(repeat units)を含む第2ポリペプチドと、
を含むことを特徴とする、局部に投与して局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止するための組成物。 - 前記第2ポリペプチドは、タンデム繰返し単位(tandem repeated units)のリニアアレイエピトープ(linear array epitope,LAE)であり、
前記第2ポリペプチドは、SEQ ID NO:14で規定される配列の6から10の繰返し単位を含むことを特徴とする、請求項1に記載の組成物。 - 前記第1ポリペプチドは、SEQ ID NO:8に対応して、7番目のアミノ酸にT又はLを有し、9番目のアミノ酸にG又はEを有し、13番目のアミノ酸にY又はVを有し、105番目のアミノ酸にH又はYを有することを特徴とする、請求項1に記載の組成物。
- 前記第1ポリペプチドは、SEQ ID NO:4、5、6、7、8、9、10、11及び12からなる群から選ばれることを特徴とする、請求項1に記載の組成物。
- 前記第1ポリペプチドと第2ポリペプチドの間にあるコネクソンをさらに有し、
前記第1ポリペプチドと前記コネクソンと前記第2ポリペプチドの配列は、SEQ ID NO:17であることを特徴とする、請求項1~4のいずれか1項に記載の組成物。 - SEQ ID NO:17に示されるアミノ酸配列からなる、請求項1~5のいずれか1項に記載の組成物であることを特徴とする、局部に投与して局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止するための組成物。
- 請求項1~5のいずれか1項に記載の組成物及び薬学的に許容される担体を含むことを特徴とする、局部に投与して局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止するための医薬組成物。
- 請求項1~5のいずれか1項に記載の組成物を使用することによって製造された、局部に投与して局部の筋肉増加を促進するための薬物。
- 請求項1~5のいずれか1項に記載の組成物を使用することによって製造された、局部に投与して局部の筋萎縮を抑制又は防止するための薬物。
- 前記組成物が、薬物による筋萎縮、神経外傷による筋萎縮、神経壊死による筋萎縮、自己免疫反応による筋萎縮、環境毒素による筋萎縮、又は外力による筋萎縮に適用される、請求項9に記載の薬物。
- 黄色ブドウ球菌エンテロトキシンのポリペプチドと、
増殖分化因子8(growth differentiation factor 8,GDF8)のC端の15個のアミノ酸の6から10の繰返し単位を含むミオスタチンポリペプチドと、
を有することを特徴とする、局部に投与して局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止するための組成物。 - 前記ミオスタチンポリペプチドは、SEQ ID NO:14で規定されるアミノ酸配列を含むC端エピトープを含むことを特徴とする、請求項11に記載の組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/079716 WO2019178759A1 (zh) | 2018-03-21 | 2018-03-21 | 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021516252A JP2021516252A (ja) | 2021-07-01 |
JP7183291B2 true JP7183291B2 (ja) | 2022-12-05 |
Family
ID=67986635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020550596A Active JP7183291B2 (ja) | 2018-03-21 | 2018-03-21 | 局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11672845B2 (ja) |
EP (1) | EP3769779B1 (ja) |
JP (1) | JP7183291B2 (ja) |
CN (1) | CN111902157B (ja) |
WO (1) | WO2019178759A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009545313A (ja) | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
CN102060916A (zh) | 2010-09-08 | 2011-05-18 | 沈阳协合生物制药股份有限公司 | 肠毒素c2超抗原突变蛋白和编码基因及其制备和应用 |
JP2012244994A (ja) | 2011-05-27 | 2012-12-13 | National Cheng Kung Univ | 脊椎動物用の食品組成物 |
CN105983096A (zh) | 2015-03-04 | 2016-10-05 | 中国科学院沈阳应用生态研究所 | Sec的应用及抗病毒疫苗佐剂和复合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1729793B1 (en) * | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
WO2010129406A2 (en) * | 2009-05-04 | 2010-11-11 | The Johns Hopkins University | Methods of promoting muscle growth |
WO2011040823A1 (en) * | 2009-10-01 | 2011-04-07 | Covita Limited | Synthetic myostatin peptide antagonists |
CN102114239A (zh) * | 2010-12-14 | 2011-07-06 | 孙嘉琳 | 细胞因子-超抗原融合蛋白在制备抗癌药物的应用 |
TWI540968B (zh) | 2011-05-27 | 2016-07-11 | 國立成功大學 | 降低飼料轉換率之方法 |
BR112016028520A2 (pt) * | 2014-06-04 | 2017-10-24 | Acceleron Pharma Inc | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina |
WO2016201377A1 (en) * | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
WO2019179361A1 (zh) * | 2018-03-21 | 2019-09-26 | 傅惠芳 | 改善括约肌闭锁不全的组合物及其医药组成物与用途 |
-
2018
- 2018-03-21 CN CN201880090991.3A patent/CN111902157B/zh active Active
- 2018-03-21 EP EP18910803.8A patent/EP3769779B1/en active Active
- 2018-03-21 US US16/981,391 patent/US11672845B2/en active Active
- 2018-03-21 JP JP2020550596A patent/JP7183291B2/ja active Active
- 2018-03-21 WO PCT/CN2018/079716 patent/WO2019178759A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009545313A (ja) | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
CN102060916A (zh) | 2010-09-08 | 2011-05-18 | 沈阳协合生物制药股份有限公司 | 肠毒素c2超抗原突变蛋白和编码基因及其制备和应用 |
JP2012244994A (ja) | 2011-05-27 | 2012-12-13 | National Cheng Kung Univ | 脊椎動物用の食品組成物 |
CN105983096A (zh) | 2015-03-04 | 2016-10-05 | 中国科学院沈阳应用生态研究所 | Sec的应用及抗病毒疫苗佐剂和复合物 |
Non-Patent Citations (2)
Title |
---|
Biochemical and Biophysical Research communications,2003年,Vol.300,pp.965-971 |
J. Vet. Med. Sci.,1996年,Vol.58, No.11,pp.J46-50 |
Also Published As
Publication number | Publication date |
---|---|
US20210008165A1 (en) | 2021-01-14 |
JP2021516252A (ja) | 2021-07-01 |
EP3769779B1 (en) | 2023-12-27 |
EP3769779A1 (en) | 2021-01-27 |
CN111902157B (zh) | 2023-08-04 |
US11672845B2 (en) | 2023-06-13 |
EP3769779C0 (en) | 2023-12-27 |
CN111902157A (zh) | 2020-11-06 |
WO2019178759A1 (zh) | 2019-09-26 |
EP3769779A4 (en) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dalum et al. | Therapeutic antibodies elicited by immunization against TNF-α | |
US10570193B2 (en) | Binding moieties for biofilm remediation | |
Nisbet et al. | Protection of ewes against Teladorsagia circumcincta infection in the periparturient period by vaccination with recombinant antigens | |
EA011583B1 (ru) | Миметические антитела glp-1 человека, композиции, способы и применения | |
US11299527B2 (en) | Long-acting recombinant porcine FSH fusion protein and preparation method and application thereof | |
JPH01502669A (ja) | 精製された血小板由来の成長因子及びその精製方法 | |
Yan et al. | Vaccination of goats with DNA vaccine encoding Dim-1 induced partial protection against Haemonchus contortus: A preliminary experimental study | |
WO2017192594A1 (en) | Binding moieties for biofilm remediation | |
WO2004002527A1 (ja) | 抗鶏コクシジウム症組成物 | |
RU2501565C2 (ru) | Слитый белок дефектная хлорамфеникол ацетилтрансфераза (сат)-соматостатин и его применения | |
WO2016154491A1 (en) | Binding moieties for biofilm remediation | |
TWI649332B (zh) | Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof | |
EP1657248B1 (en) | Vaccine for preventing and treating porcine progressive atrophic rhinitis | |
CN102482334A (zh) | Sparc血管发生结构域及使用方法 | |
JP7183291B2 (ja) | 局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物 | |
JP2015524802A (ja) | キメラospa分子を含む組成物およびその使用方法 | |
US8067203B2 (en) | Composition for treating porcine progressive atrophic rhinitis and making process thereof | |
US11400151B2 (en) | Methods for improving immunological response in vaccinated animals | |
EP3883603B1 (en) | Igm protease antigen vaccine for protecting against streptococcus suis | |
US11661444B2 (en) | Recombinant vaccine against proliferative enteropathy in animals | |
FANG et al. | Immunization of male mice with a new recombinant GnRH fusion protein reduces the testicular function | |
Geale et al. | Efficacy of two adjuvant systems to promote humoral immunity to the pre-proghrelin peptide obestatin in pigs: consequences for the growth of piglets to weaning | |
EP3993827A1 (en) | Parasitic nematode vaccine | |
CN102858362A (zh) | Sparc 血管生成结构域和使用方法 | |
WO2007025349A1 (en) | Modulating ovulation and growth rates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201005 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201005 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20201130 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210204 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220930 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220930 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221011 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221018 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7183291 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |